Off-label Indication |
No. of patients for each
indication (%) |
UpToDate |
Micromedex |
Guidelines |
Takayasu Arteritis |
27(16.2%) |
Effective |
_ |
Recommend[5] |
Adult-onset Still’s Disease |
13(7.8%) |
Effective |
_ |
_ |
Systemic Lupus Erythematosus |
2(1.2%) |
_ |
_ |
Not
Recommended[6-8] |
Systemic Vasculitis |
13(7.8%) |
_ |
_ |
Not
Recommended[9, 10] |
Relapsing Polychondritis |
4(2.4%) |
Effective |
_ |
_ |
Behcet’s disease |
8(4.8%) |
_ |
_ |
Recommended(Recommendation 9: nervous system
involvement :limited studies have shown some efficacy of
tocilizumab)[11]
Recommended(IL-6
inhibitors may be effective in reducing post uveitis and macular edema
in BD)[12]
|
Sjögren’s Syndrome |
4(2.4%) |
_ |
_ |
Not
Recommended[13, 14] |
Dermatomyositis |
5(3.0%) |
_ |
_ |
Not
Recommended[15, 16] |
Systemic Scleroderma |
4(2.4%) |
Effective |
_ |
_ |
Neuromyelitis Optic Spectrum
Disease |
1(0.6%) |
Effective |
_ |
_ |
Polymyalgia Rheumatica |
1(0.6%) |
_ |
_ |
Recommended[17, 18] |
Immune-mediated Necrotizing Myopathy |
1(0.6%) |
_ |
_ |
_ |
Ankylosing Spondylitis |
1(0.6%) |
Not Effective |
_ |
Not
Recommended[19] |
Psoriatic Arthritis |
1(0.6%) |
_ |
_ |
Not
Recommended[20, 21] |